The latest issue of the HPRA Drug Safety Newsletter (DSN) includes important updates to support safe and appropriate use of the following medicines:
- Valproate-containing medicines: Recommendation to further restrict use in women and girls
- Ivabradine (Procorlan): New contraindication and recommendations to minimise the risk of cardiovascular adverse events
- Agomelatine (Valdoxan): Reminder of the importance of hepatic monitoring to reduce the risk of serious hepatic adverse reactions
- Testosterone: EU review does not confirm increased risk of cardiovascular events